



# Nuvaxovid, recombinant COVID-19 Vaccine

## Information for healthcare professionals to support delivery of the Novavax COVID-19 vaccine, Nuvaxovid

### Key information

- Vaccine type: Adjuvanted recombinant spike protein subunit vaccine
- Immunisation Handbook abbreviation: rCV
- Two doses given at least 21 days apart, ideally 8 weeks apart, for use from age 18 years.

The preferred COVID-19 vaccine is Comirnaty (30 mcg; Pfizer), however Nuvaxovid (Novavax) may be offered to individuals aged 18 years or over: who are contraindicated Comirnaty; who have experienced a severe adverse event following Comirnaty vaccination; or who have declined Comirnaty or AstraZeneca COVID-19 vaccine for personal preference. Use as a second dose after a first dose of Comirnaty or AstraZeneca, or if given to individuals aged 12-17 years as a primary course, requires a prescription. A prescription is not required when Nuvaxovid is given as a booster dose to those aged 18 years or over.

### Background

Nuvaxovid contains recombinant SARS-CoV-2 spike protein in a stabilised prefusion conformation combined with Matrix-M adjuvant to form immunogenic nanoparticles. The spike protein is produced by an insect cell-line that has been infected with an insect baculovirus expressing SARS-CoV-2 spike protein genes. The proprietary adjuvant (Matrix-M) contains two purified saponin fractions from *Quillaja saponaria* (soapbark tree) which enhances the innate immune response and activates the production of neutralising antibodies and T and B cell immunity

The vaccine was designated NVX-2373 in clinical trials conducted by Novavax. It is sponsored in New Zealand by Bioelect and is approved by Medsafe for the prevention of COVID-19 in individuals aged 18 years or over.

### Efficacy in clinical trials

Note that most of the clinical trials were conducted during early 2021, against predominantly Alpha not Delta nor Omicron variants. Real world data on effectiveness of Nuvaxovid is limited as the vaccine has only recently been approved for use.

#### **Primary course: homologous**

An overall vaccine efficacy against symptomatic COVID-19 of 90% from 7 days after dose two of Nuvaxovid was shown across two phase III clinical trials involving over 45,000 participants (95% CI 82.9–94.6 in PREVENT-19 study in US/Mexico and 80.2–94.6% in a UK trial).(1,2) Protection was similar in participants aged 18-64 and 65-84 years and in those with coexisting illness. As reported by Novavax, vaccine efficacy was maintained over six months in the UK trial (from 10 November 2020 to 10 May 2021) with an overall vaccine efficacy of 82.5% (95% CI: 75.0–87.7) in protection against all COVID-19 infection – both symptomatic and asymptomatic – as measured by PCR+ or anti-N seroconversion, and efficacy against severe disease of 100% (95% CI: 17.9, 100).(3)

#### **Primary course: heterologous/mixed**

In those who have had a severe adverse reaction to their first dose of either Comirnaty or AstraZeneca, Nuvaxovid may be used for their second dose, given at least 28 days after the first dose. This is off-label use and will require prescription from an authorised provider (in accordance with Section 25 of the Medicines Act,1981).

Nuvaxovid has been shown to induce a good antibody response when given as a second dose after either a first dose of Comirnaty or AstraZeneca vaccines. A phase II study in the UK investigated safety and immunogenicity of mixed primary schedules. Between April and May 2021, 1,072 participants aged 50–78 years received a second dose of one of three COVID-19 vaccines a median of 9.4 weeks after receipt of a single dose of either the AstraZeneca or Comirnaty vaccines.(5) Although, the antibody response after a dose of Nuvaxovid was not as high as after a second dose of Comirnaty, an 18-fold rise in anti-spike antibody concentration was seen 28 days after vaccination. This was higher than after two doses of AstraZeneca vaccine. For those who received a first dose of AstraZeneca, a second dose with Nuvaxovid induced a better antibody response as a second dose of AstraZeneca.

### ***Booster doses: homologous***

Early data supports the safety and effectiveness of the use of Nuvaxovid as a booster dose.

The immune responses were enhanced when a booster dose was given approximately six months after the two-dose primary course, as shown in a phase II clinical trial assessing the immunogenicity. For both Delta and Omicron, immune responses following the booster were notably higher than those associated with high levels of efficacy in phase III studies of the vaccine.(4)

### ***Booster doses: heterologous/mixed***

In the UK COV-BOOST study participants aged 30 years or over with no history of laboratory-confirmed SARS-CoV-2 infection were given one of six vaccines as a booster dose at least 84 days post two doses of Comirnaty or at least 70 days post two doses of AstraZeneca.(6) Following a Comirnaty primary series, the neutralising antibody titre after a dose of Nuvaxovid was 2.7–5.4 greater than the control, while a Comirnaty booster induced 5.8–8.4 higher antibody titres. Thus, for those who experience severe adverse events to their second dose of Comirnaty vaccine, Nuvaxovid would be an effective booster although it appears less immunogenic than Comirnaty as a booster dose.

### **Vaccine safety**

Since this vaccine has not been widely used yet, the safety data is limited and largely based on clinical trials. Passive and active safety surveillance is underway in numerous countries, including Australia and the UK.

*Contraindication:* Nuvaxovid is contraindicated for individuals with a history of anaphylaxis to previous dose of this vaccine or to any component of the vaccine, including, polysorbate 80 or saponin. See the Medsafe data sheet for contents.(7)

*Potential responses:* The most reported responses during clinical trials were pain and swelling at the injection site (approximately 4 out of 5 dose 2 recipients), headache, muscle pain and fatigue (each, approximately 1-2 in 5 recipients). These are short in duration and more common after the second dose and in younger recipients. (2, 4) Similar frequencies in serious adverse events were observed between vaccine and placebo groups during clinical trials. When Nuvaxovid was given as a second dose after Comirnaty, the frequency of local and systemic responses were generally less than after a second dose of Comirnaty.(5) Booster doses are also associated with higher rates (82.5%) of adverse responses than the primary series.

*Adverse events following immunisation:* uncommon adverse events reported during clinical trials were lymphadenopathy and hypertension (reported one in ten older participants within three days of vaccination), rash and injection-site itching. Cases of myocarditis and pericarditis were identified in clinical trials of Nuvaxovid and have been reported during post-authorisation use: a rare but increased risk for these conditions may be present after receiving Nuvaxovid. Post-marketing experience also includes reports of decreased or painful skin sensations.

### **Use in pregnancy**

Since pregnant women were excluded from the clinical trials, there is insufficient safety data to date to recommend Nuvaxovid for use during pregnancy. Pregnant people are advised to discuss the benefit and potential risks of receiving this vaccine in pregnancy with their health professional. Comirnaty is the preferred COVID-19 in pregnancy. There are no safety concerns should it be given inadvertently in pregnancy and no potentially harmful effects were noted in preclinical studies.

### **Use when breastfeeding**

There is limited data to date around the use of Nuvaxovid in lactating women. Although as with all National Immunisation Schedule vaccines, there are no concerns about giving vaccines to individuals who are lactating, the safety of Matrix M adjuvant has not yet been evaluated in human breastmilk. Prior to administration, breastfeeding women are encouraged to discuss benefit and risk with their health professional.

### **Coadministration with other vaccines**

Nuvaxovid can be given at the same time, before or after as most of the available vaccines, including season influenza vaccine, Boostrix and MMR. Use different needles and different injection sites. The exceptions are other liposome adjuvant vaccines, namely Shingrix (recombinant zoster vaccine) and adjuvanted influenza vaccine (Fluad Quad) – allow 3 days before or after Nuvaxovid.

### **References**

1. Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. *New England Journal of Medicine*, 2022. 386: p. 531-543
2. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. *New England Journal of Medicine*, 2021. 385(13): p. 1172-1183
3. <https://ir.novavax.com/2022-02-28-Novavax-Announces-Extended-Durability-of-Protection-Against-Infection-and-Disease-in-United-Kingdom-COVID-19-Vaccine-Phase-3-Clinical-Trial> (accessed 11 March)
4. Mallory R, Formica N, Pfeiffer S, et al. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A phase 2 randomized placebo-controlled trial. *medRxiv*, 2021 (preprint): p. 2021.12.23.21267374.
5. Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. *Lancet*, 2022. 399(10319): p. 36-49.
6. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *Lancet*, 2021. 398(10318): p. 2258-2276.
7. Medsafe. New Zealand Data sheet: Nuvaxovid COVID-19 vaccine. Available from: <https://www.medsafe.govt.nz/profs/Datasheet/n/Nuvaxovidinj.pdf> (accessed 15 March 2022)
8. European Medicines Agency. CHMP assessment report: Nuvaxovid. Online; 2022 04 January 2022. Report No.: EMA/783213/2021. Available from: [https://www.ema.europa.eu/en/documents/assessment-report/nuvaxovid-epar-public-assessment-report\\_en.pdf](https://www.ema.europa.eu/en/documents/assessment-report/nuvaxovid-epar-public-assessment-report_en.pdf) (accessed 15 March 2022)

**CALL 0800 IMMUNE (466 863) for clinical advice**